Actively Recruiting
Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech Republic
Led by Charles University, Czech Republic · Updated on 2025-12-10
209
Participants Needed
4
Research Sites
191 weeks
Total Duration
On this page
Sponsors
C
Charles University, Czech Republic
Lead Sponsor
Č
České Budějovice Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This observational study follows children and adults who were hospitalized with tick-borne encephalitis (TBE) in the Czech Republic. The aim is to better understand how individuals recover from TBE, which symptoms may persist after the infection, and which patients may require additional support during their recovery. Participants are examined several times after hospital discharge (at 2-4 weeks, 3 months, 6 months, and 12 months) to observe changes in symptoms, functional status, and daily activities. Follow-up assessments include evaluation of common post-infection problems such as tiredness, headaches, memory or concentration difficulties, sleep issues, or limb weakness. Symptoms lasting for several months are categorized as post-encephalitic syndrome (PES). The study also assesses how TBE affects daily functioning, school and work performance, and overall quality of life using questionnaires and short functional assessments. In addition, the study includes a public-health component that estimates the broader impact of TBE in the population and evaluates the potential benefits of vaccination in preventing long-term health complications. The findings aim to support improved patient care, follow-up planning, and evidence-based public-health decision-making in the Czech Republic.
CONDITIONS
Official Title
Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech Republic
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospitalization due to suspected central nervous system (CNS) infection.
- Laboratory-confirmed tick-borne encephalitis (TBE) with CNS symptoms and cerebrospinal fluid pleocytosis (>5 × 10⁶/L) and TBEV IgM and IgG seropositivity in serum, or TBEV IgM detection in CSF in previously vaccinated individuals.
- All age groups including children and adults.
- Ability to participate in scheduled follow-up visits in person or via telephone.
- Informed consent provided by the patient or legal guardian for minors.
You will not qualify if you...
- Alternative diagnosis explaining the central nervous system symptoms.
- Missing essential clinical or laboratory data to confirm TBE or assess outcomes.
- Refusal or inability to provide informed consent.
- Inability to complete follow-up assessments or maintain reliable contact.
- Coexisting severe neurological disorder unrelated to TBE that prevents meaningful evaluation of sequelae, such as advanced neurodegenerative disease or severe preexisting motor disability.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Ostrava University Hospital
Ostrava, Moravian-Silesian Region, Czechia, 70800
Actively Recruiting
2
Pardubická nemocnice
Pardubice, Pardubice Region, Czechia, 53001
Actively Recruiting
3
Bulovka University Hospital
Prague, Prague, Czechia, 18081
Actively Recruiting
4
České Budějovice Hospital
České Budějovice, South Bohemian Region, Czechia, 37001
Actively Recruiting
Research Team
M
Martin Slížek, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here